Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men.
Roivainen A, Kähkönen E, Luoto P, Borkowski S, Hofmann B, Jambor I, Lehtiö K, Rantala T, Rottmann A, Sipilä H, Sparks R, Suilamo S, Tolvanen T, Valencia R, Minn H. Roivainen A, et al. Among authors: suilamo s. J Nucl Med. 2013 Jun;54(6):867-72. doi: 10.2967/jnumed.112.114082. Epub 2013 Apr 5. J Nucl Med. 2013. PMID: 23564761 Free article. Clinical Trial.
¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men.
Luoto P, Suilamo S, Oikonen V, Arponen E, Helin S, Herttuainen J, Hietamäki J, Holopainen A, Kailajärvi M, Peltonen JM, Rouru J, Sallinen J, Scheinin M, Virta J, Virtanen K, Volanen I, Roivainen A, Rinne JO. Luoto P, et al. Among authors: suilamo s. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1947-56. doi: 10.1007/s00259-014-2782-y. Epub 2014 May 17. Eur J Nucl Med Mol Imaging. 2014. PMID: 24838249
First-in-Humans Study of 68Ga-DOTA-Siglec-9, a PET Ligand Targeting Vascular Adhesion Protein 1.
Viitanen R, Moisio O, Lankinen P, Li XG, Koivumäki M, Suilamo S, Tolvanen T, Taimen K, Mali M, Kohonen I, Koskivirta I, Oikonen V, Virtanen H, Santalahti K, Autio A, Saraste A, Pirilä L, Nuutila P, Knuuti J, Jalkanen S, Roivainen A. Viitanen R, et al. Among authors: suilamo s. J Nucl Med. 2021 Apr;62(4):577-583. doi: 10.2967/jnumed.120.250696. Epub 2020 Aug 17. J Nucl Med. 2021. PMID: 32817143 Free PMC article.
Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy.
Kiviniemi A, Gardberg M, Frantzén J, Pesola M, Vuorinen V, Parkkola R, Tolvanen T, Suilamo S, Johansson J, Luoto P, Kemppainen J, Roivainen A, Minn H. Kiviniemi A, et al. Among authors: suilamo s. EJNMMI Res. 2015 Apr 22;5:25. doi: 10.1186/s13550-015-0106-2. eCollection 2015. EJNMMI Res. 2015. PMID: 25977882 Free PMC article.
Repeatability of tumour hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer.
Silvoniemi A, Suilamo S, Laitinen T, Forsback S, Löyttyniemi E, Vaittinen S, Saunavaara V, Solin O, Grönroos TJ, Minn H. Silvoniemi A, et al. Among authors: suilamo s. Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):161-169. doi: 10.1007/s00259-017-3857-3. Epub 2017 Oct 26. Eur J Nucl Med Mol Imaging. 2018. PMID: 29075831 Free PMC article. Clinical Trial.
24 results